FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894793631> ?p ?o ?g. }

• W2894793631 abstract "Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to monotherapy blockade of programmed cell death protein 1 receptor, programmed death ligand 1, and cytotoxic T-lymphocyte associated protein 4. However, there is a growing body of preclinical evidence to support the rational combination of checkpoint inhibitors and various systemic therapies in pancreatic cancer. Furthermore, early clinical evidence has begun to support the feasibility and efficacy of checkpoint inhibitor-based combination therapy in advanced pancreatic cancer. Despite accumulating preclinical and clinical data, there remains several questions as to the optimal dosing and timing of administration of respective agents, toxicity of combination strategies, and mechanisms by which immune resistance to single-agent checkpoint blockade are overcome. Further development of biomarkers is also important in the advancement of combination systemic therapies incorporating checkpoint blockade in pancreatic cancer. Results from an impressive number of ongoing prospective clinical trials are eagerly anticipated and will seek to validate the viability of combination immuno-oncology strategies in pancreatic cancer." @default.
• W2894793631 created "2018-10-12" @default.
• W2894793631 creator A5003826371 @default.
• W2894793631 creator A5021322394 @default.
• W2894793631 creator A5022022603 @default.
• W2894793631 creator A5024750927 @default.
• W2894793631 creator A5027630636 @default.
• W2894793631 creator A5037942451 @default.
• W2894793631 creator A5080105357 @default.
• W2894793631 creator A5084571872 @default.
• W2894793631 date "2018-10-08" @default.
• W2894793631 modified "2023-10-16" @default.
• W2894793631 title "Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade" @default.
• W2894793631 cites W1942897646 @default.
• W2894793631 cites W1955557233 @default.
• W2894793631 cites W1966648901 @default.
• W2894793631 cites W1977310989 @default.
• W2894793631 cites W1997944395 @default.
• W2894793631 cites W2033577259 @default.
• W2894793631 cites W2044363258 @default.
• W2894793631 cites W2054373401 @default.
• W2894793631 cites W2060469376 @default.
• W2894793631 cites W2070825440 @default.
• W2894793631 cites W2086526310 @default.
• W2894793631 cites W2086834665 @default.
• W2894793631 cites W2101653483 @default.
• W2894793631 cites W2124427232 @default.
• W2894793631 cites W2132290857 @default.
• W2894793631 cites W2137217704 @default.
• W2894793631 cites W2141360391 @default.
• W2894793631 cites W2150048477 @default.
• W2894793631 cites W2154753744 @default.
• W2894793631 cites W2161558877 @default.
• W2894793631 cites W2219050650 @default.
• W2894793631 cites W2257916459 @default.
• W2894793631 cites W2291579888 @default.
• W2894793631 cites W2295620064 @default.
• W2894793631 cites W2324865626 @default.
• W2894793631 cites W2416038770 @default.
• W2894793631 cites W2416541866 @default.
• W2894793631 cites W2424046217 @default.
• W2894793631 cites W2461513545 @default.
• W2894793631 cites W2462427156 @default.
• W2894793631 cites W2469223980 @default.
• W2894793631 cites W2505222127 @default.
• W2894793631 cites W2537220355 @default.
• W2894793631 cites W2560367415 @default.
• W2894793631 cites W2564351475 @default.
• W2894793631 cites W2572174216 @default.
• W2894793631 cites W2582362986 @default.
• W2894793631 cites W2586424458 @default.
• W2894793631 cites W2587048937 @default.
• W2894793631 cites W2587486634 @default.
• W2894793631 cites W2599133172 @default.
• W2894793631 cites W2599857500 @default.
• W2894793631 cites W2603775838 @default.
• W2894793631 cites W2606837173 @default.
• W2894793631 cites W2621755511 @default.
• W2894793631 cites W2742057624 @default.
• W2894793631 cites W2742508023 @default.
• W2894793631 cites W2746455523 @default.
• W2894793631 cites W2750317630 @default.
• W2894793631 cites W2752227448 @default.
• W2894793631 cites W2753065806 @default.
• W2894793631 cites W2753127414 @default.
• W2894793631 cites W2759607867 @default.
• W2894793631 cites W2765135646 @default.
• W2894793631 cites W2765943070 @default.
• W2894793631 cites W2766179432 @default.
• W2894793631 cites W2767034994 @default.
• W2894793631 cites W2767403472 @default.
• W2894793631 cites W2770412757 @default.
• W2894793631 cites W2771707944 @default.
• W2894793631 cites W2772648968 @default.
• W2894793631 cites W2773161575 @default.
• W2894793631 cites W2775658849 @default.
• W2894793631 cites W2781947653 @default.
• W2894793631 cites W2782007611 @default.
• W2894793631 cites W2785495519 @default.
• W2894793631 cites W2788587230 @default.
• W2894793631 cites W2789892285 @default.
• W2894793631 cites W2790589159 @default.
• W2894793631 cites W2790748515 @default.
• W2894793631 cites W2791084081 @default.
• W2894793631 cites W2793752308 @default.
• W2894793631 cites W2793938850 @default.
• W2894793631 cites W2794577178 @default.
• W2894793631 cites W2794947731 @default.
• W2894793631 cites W2796894486 @default.
• W2894793631 cites W2797309423 @default.
• W2894793631 cites W2798160602 @default.
• W2894793631 cites W2806383117 @default.
• W2894793631 cites W4249227756 @default.
• W2894793631 doi "https://doi.org/10.1186/s40169-018-0210-9" @default.
• W2894793631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6174117" @default.
• W2894793631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30294755" @default.
• W2894793631 hasPublicationYear "2018" @default.
• W2894793631 type Work @default.
• W2894793631 sameAs 2894793631 @default.
• W2894793631 citedByCount "27" @default.

• next